Free Trial

Immunocore (IMCR) Competitors

Immunocore logo
$36.31 +0.10 (+0.28%)
Closing price 04:00 PM Eastern
Extended Trading
$36.29 -0.02 (-0.06%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IMCR vs. GRFS, TGTX, NUVL, LNTH, RYTM, AXSM, TLX, CRSP, PCVX, and CYTK

Should you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Rhythm Pharmaceuticals (RYTM), Axsome Therapeutics (AXSM), Telix Pharmaceuticals (TLX), CRISPR Therapeutics (CRSP), Vaxcyte (PCVX), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry.

Immunocore vs. Its Competitors

Grifols (NASDAQ:GRFS) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, Grifols had 4 more articles in the media than Immunocore. MarketBeat recorded 5 mentions for Grifols and 1 mentions for Immunocore. Immunocore's average media sentiment score of 0.85 beat Grifols' score of 0.58 indicating that Immunocore is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Grifols
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Immunocore
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

84.5% of Immunocore shares are held by institutional investors. 0.2% of Grifols shares are held by insiders. Comparatively, 10.4% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Grifols presently has a consensus target price of $10.30, indicating a potential upside of 3.62%. Immunocore has a consensus target price of $58.89, indicating a potential upside of 62.18%. Given Immunocore's higher probable upside, analysts clearly believe Immunocore is more favorable than Grifols.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Grifols
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00
Immunocore
1 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.55

Grifols has higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Grifols$7.81B0.88$169.80M$1.178.50
Immunocore$310.20M5.88-$51.09M-$0.43-84.44

Grifols has a net margin of 0.00% compared to Immunocore's net margin of -6.48%. Grifols' return on equity of 0.00% beat Immunocore's return on equity.

Company Net Margins Return on Equity Return on Assets
GrifolsN/A N/A N/A
Immunocore -6.48%-5.86%-2.09%

Grifols has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Summary

Grifols beats Immunocore on 9 of the 16 factors compared between the two stocks.

Get Immunocore News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMCR vs. The Competition

MetricImmunocoreMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.82B$2.96B$5.54B$9.41B
Dividend YieldN/A2.46%3.75%4.03%
P/E RatioN/A8.2821.0120.09
Price / Sales5.88303.17433.8199.01
Price / CashN/A42.5936.1658.27
Price / Book5.047.678.125.65
Net Income-$51.09M-$55.28M$3.25B$257.91M
7 Day Performance3.68%2.50%0.97%2.09%
1 Month Performance14.54%11.70%7.36%11.13%
1 Year Performance-6.59%4.89%31.31%18.40%

Immunocore Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMCR
Immunocore
1.333 of 5 stars
$36.31
+0.3%
$58.89
+62.2%
-7.2%$1.82B$310.20M0.00320
GRFS
Grifols
3.8994 of 5 stars
$9.72
-0.2%
$10.30
+6.0%
+24.7%$6.68B$7.81B8.3123,822News Coverage
TGTX
TG Therapeutics
3.4049 of 5 stars
$38.92
+5.0%
$43.80
+12.5%
+77.5%$6.18B$329M162.17290
NUVL
Nuvalent
3.1882 of 5 stars
$84.59
+4.5%
$119.60
+41.4%
+6.4%$6.07BN/A-19.2740Insider Trade
LNTH
Lantheus
4.6282 of 5 stars
$83.06
+2.2%
$131.20
+58.0%
-39.5%$5.75B$1.53B23.60700News Coverage
Positive News
Analyst Forecast
RYTM
Rhythm Pharmaceuticals
3.1928 of 5 stars
$89.15
+2.8%
$91.00
+2.1%
+74.1%$5.67B$130.13M-31.73140Analyst Forecast
Analyst Revision
AXSM
Axsome Therapeutics
4.7309 of 5 stars
$112.33
+3.1%
$172.33
+53.4%
+34.0%$5.53B$385.69M-19.47380Analyst Revision
TLX
Telix Pharmaceuticals
N/A$15.57
-2.5%
$22.33
+43.4%
N/A$5.27B$783.21M0.00N/AAnalyst Revision
CRSP
CRISPR Therapeutics
2.69 of 5 stars
$56.42
-0.7%
$71.75
+27.2%
-8.9%$4.87B$37.31M-12.48460Insider Trade
Analyst Revision
Gap Up
PCVX
Vaxcyte
1.8072 of 5 stars
$36.38
+1.3%
$136.50
+275.2%
-54.1%$4.69BN/A-9.12160Positive News
CYTK
Cytokinetics
4.0425 of 5 stars
$38.58
+4.2%
$70.92
+83.8%
-31.5%$4.61B$18.47M-7.29250Insider Trade

Related Companies and Tools


This page (NASDAQ:IMCR) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners